Every letter we have printed
Page 2 of 77 of this archive, newest first.
On “Four millimetres is enough, and the data says so” — Patient Notes, 18 Jun 2026
The section on in-use stability is unhelpfully agnostic. Everyone in this market uses a figure of around thirty days refrigerated. Surely you can say whether that is roughly right rather than declining to comment.
— O. Brannigan, Galway
We can say where it comes from, which is the in-use period established for licensed pen presentations of specific formulations in specific containers. Whether it transfers to a different peptide reconstituted in a different diluent in a different vial is not something the stability literature permits anyone to assert. Declining to guess is not agnosticism; it is the difference between a study and a convention.
On “Four millimetres is enough, and the data says so” — Patient Notes, 18 Jun 2026
As a practice nurse I would add the ten-second hold to your list of things people skip. I watch patients withdraw immediately and then wonder about the wet patch on their skin. It is the most visible underdose there is and almost nobody connects the two.
— G. Papadakis, Thessaloniki
Well observed, and now in the priming section and the sidebar. The wet skin is exactly the useful feedback signal — unlike most of the errors in this file, this one announces itself, and the announcement is being misread.
On “Four millimetres is enough, and the data says so” — Patient Notes, 18 Jun 2026
Your rotation advice says site does not affect absorption in this class, and then says to rotate anyway. If absorption is unaffected, why bother?
— N. Fairweather, Hamilton
Because rotation protects tissue rather than controlling absorption. Repeated injection into one small area produces lipohypertrophy, and absorption from lipohypertrophic tissue is blunted and erratic for any injected depot. Rotation prevents the condition that would make site matter. The advice is consistent; we should have made the causal order clearer.
On “Four millimetres is enough, and the data says so” — Patient Notes, 18 Jun 2026
I have accumulated about eighteen months of used needles in a plastic tub because I did not know where to take them and assumed I would be asked questions. Your paragraph on this is the first time I have seen the situation described rather than lectured about.
— M. Karlsen, Kristiansand
Collection services are not interested in what was in the syringe. A pharmacy or local authority sharps point will take a rigid sealed container without inquiry, and the barrier you describe is built entirely of anticipated judgement. We would rather say that plainly than add to the lecturing.
On “One method is one opinion” — Laboratory Notebook, 17 Jun 2026
Your worked example varies gradient and threshold together and reports a 1.8-point spread. Which of the two contributed more? The article does not say, and the answer matters for what you are asking suppliers to disclose first.
— R. Cadogan, Bridgetown
Gradient, by roughly two to one in our four conditions: holding the threshold at 0.10 per cent, lengthening the gradient cost 0.9 points, while holding the gradient and tightening the threshold cost 0.4 to 0.9 depending on which gradient. We should have printed that decomposition in the table and it now appears in the note. If a supplier will disclose only one value, it should be the gradient.
On “A reference interval is not a target, and a result outside one is not a…” — Clinical Trials, 17 Jun 2026
You describe the low-T3 pattern during energy restriction as benign adaptation. There is a body of opinion holding that it represents a genuine hypometabolic state requiring treatment. I do not hold that view but your readers will encounter it.
— C. Bąkowski, Łódź
They will, and we should have named it in order to say why we do not report it. There is no randomised evidence that treating the low-T3 pattern of energy restriction improves any outcome, and there is a mechanistic argument that suppressing an adaptive response is unlikely to help. We report it as adaptation for those reasons and would report a trial that changed the picture.
On “A reference interval is not a target, and a result outside one is not a…” — Clinical Trials, 17 Jun 2026
My HbA1c was 6.1 before starting and 6.0 after four months. My clinic recorded this as no improvement in glycaemic control. My continuous monitor says my average glucose fell by a fifth over the same period. Which is measuring what?
— D. Sakamoto, Kobe
Both are measuring correctly and the discrepancy is worth pursuing with your clinic rather than with us. A 0.1-point change is well inside the reference change value for HbA1c, so the assay has not detected a change; whether that is because the change is genuinely small or because something is affecting your glycation is not answerable from the numbers alone.
On “Seven days, four weeks, one number: how liraglutide exposure actually…” — Pharmacology, 16 Jun 2026
I have been on treatment for fourteen months and stopped losing weight at month eleven. Your piece says this is energy balance rather than receptor desensitisation. I would find that easier to accept if anybody had explained it to me at the start rather than after I had spent two months assuming the drug had stopped working.
— J. Halloway, Dundee
That is a fair criticism of the field rather than of this article, and we take the point about timing. The plateau is predictable and predicted; it is very rarely mentioned before it happens.
On “Seven days, four weeks, one number: how liraglutide exposure actually…” — Pharmacology, 16 Jun 2026
A small thing: you write "class B GPCR" and then "secretin-like receptor" as though these were different classifications. They are the same family under two naming conventions, and the piece would be clearer if it said so.
— K. Oyibo, Benin City
Fair, and now stated in the text.
On “What a laboratory knows about the material it receives” — The Ledger, 14 Jun 2026
You note that no service offers sterility testing and that it takes fourteen days. Worth saying more plainly: a purity certificate and a sterility assurance are not merely different tests, they are different disciplines with different facilities, and no amount of chromatography will ever bear on it.
— S. Weatherall, Newcastle, NSW
Correct and worth the emphasis. We have said it in the certificates piece and should say it here too: nothing any of these four services sells addresses sterility, endotoxin or container closure integrity, and no combination of their reports adds up to one.
On “What a laboratory knows about the material it receives” — The Ledger, 14 Jun 2026
The price table is the most useful thing you have published this year and also the thing most likely to be quoted out of context by somebody selling a comparison service. You might consider a note.
— T. Aoyama, Nagoya
There is one, and we have strengthened it. The figures are what this publication was invoiced at list rates and are not quotations a reader should expect; volume submitters pay materially less.
On “What a laboratory knows about the material it receives” — The Ledger, 14 Jun 2026
I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.
— P. Sandoval, Albuquerque, NM
That is a better summary of this article’s practical content than our own closing paragraphs. The one thing we would add is that your result is worth publishing wherever you can, because buyer-submitted results are the scarcest and most informative category in the entire corpus.
On “What a laboratory knows about the material it receives” — The Ledger, 14 Jun 2026
I run analytical services and I object to the framing of your blind comparison. You bought our cheapest tier, published the number it produced alongside a competitor’s most thorough package, and called the result a spread. It is not a spread. It is three different products, priced accordingly, and your own table says so two columns to the right of the headline figure.
— Q. Delacroix, Montréal, QC
This is the objection we thought was most likely and we think it is partly right. The comparison is of standard products at standard prices, which is what buyers actually purchase, and we said so. But the presentation invites the reading you object to, and the figure caption now states the tier alongside each result rather than leaving it to the method columns.
On “What a laboratory knows about the material it receives” — The Ledger, 14 Jun 2026
Your suggestion that laboratories publish the fact of a submission while keeping the result confidential is the first proposal I have read in this area that a laboratory could actually implement without breaching a client obligation. I have raised it internally.
— A. Lindholm, Gothenburg
We would be glad to report the outcome either way, including if the answer is no and the reason is commercial. The proposal is only useful if somebody adopts it, and a published refusal is more informative than silence.
On “Two per cent water sounds like nothing and is not nothing” — Laboratory Notebook, 14 Jun 2026
You say no company reports residual moisture. I obtained a figure from a supplier last year without difficulty, on request, so the data exists in at least some cases. The problem may be less that it is not measured than that it is not printed.
— E. Nkomo, Polokwane
On “Two per cent water sounds like nothing and is not nothing” — Laboratory Notebook, 14 Jun 2026
I have shipped temperature-sensitive material commercially for eleven years and your coolant arithmetic is right but generous. You assume the pack starts fully frozen. In practice packs are pulled from a freezer that is opened forty times a day, and a pack that starts at minus four with a soft core has lost a fair share of its budget before the box is closed.
— J. Costanzo, Naples
A good point and one we had not considered properly. The latent heat calculation assumes a fully solid pack at its melting point, and a partially thawed pack is exactly as much worse as the missing solid fraction. We have added a sentence and would welcome any data you can share on pack condition at packing.
On “Two per cent water sounds like nothing and is not nothing” — Laboratory Notebook, 14 Jun 2026
Your section on freezing reconstituted solution stops short of the obvious question, which I will therefore ask. If a phosphate buffer shifts pH substantially on freezing, does that not mean the freezer is actively worse than the refrigerator for a buffered formulation, rather than merely unproven?
— C. Aguirre, Rosario
For a phosphate-buffered formulation, plausibly yes, and the mechanism is well documented. We stopped short because the magnitude is formulation-specific and because most reconstituted research vials are in unbuffered water or bacteriostatic water, where the argument is about the interface rather than about pH. We should have made that distinction in the text instead of leaving a gap for you to find.
On “Two per cent water sounds like nothing and is not nothing” — Laboratory Notebook, 14 Jun 2026
Eleven days in customs, and you describe it as a structural feature rather than a scandal. Why the restraint? A shipper advertising a cold chain that demonstrably does not survive a routine examination is making a claim it cannot support.
— G. Rasmussen, Odense
The restraint is about where the fault lies. Customs authorities are performing a lawful function and owe nobody a thermal record. The claim of end-to-end control is the thing we criticise, and we do criticise it, in the article and again in the closing. What we will not do is convert an unavoidable feature of international freight into an allegation against the shipper who could not see it either.
On “Two per cent water sounds like nothing and is not nothing” — Laboratory Notebook, 14 Jun 2026
On amber glass: it is not merely cheap, it is standard in the wider chemical supply trade for anything with a chromophore. The fact that this market ships peptides in clear glass is a sign of who is doing the filling more than of any decision about photostability.
— N. Prasetyo, Surabaya
On “The badge is about a sample. The listing is about a product.” — Analytics, 13 Jun 2026
The price table is the most useful thing you have published this year and also the thing most likely to be quoted out of context by somebody selling a comparison service. You might consider a note.
— P. Sarkissian, Beirut
There is one, and we have strengthened it. The figures are what this publication was invoiced at list rates and are not quotations a reader should expect; volume submitters pay materially less.
On “The badge is about a sample. The listing is about a product.” — Analytics, 13 Jun 2026
You note that no service offers sterility testing and that it takes fourteen days. Worth saying more plainly: a purity certificate and a sterility assurance are not merely different tests, they are different disciplines with different facilities, and no amount of chromatography will ever bear on it.
— J. Delahunty, Waterford
Correct and worth the emphasis. We have said it in the certificates piece and should say it here too: nothing any of these four services sells addresses sterility, endotoxin or container closure integrity, and no combination of their reports adds up to one.
On “The badge is about a sample. The listing is about a product.” — Analytics, 13 Jun 2026
I run analytical services and I object to the framing of your blind comparison. You bought our cheapest tier, published the number it produced alongside a competitor’s most thorough package, and called the result a spread. It is not a spread. It is three different products, priced accordingly, and your own table says so two columns to the right of the headline figure.
— N. Prasetyo, Surabaya
This is the objection we thought was most likely and we think it is partly right. The comparison is of standard products at standard prices, which is what buyers actually purchase, and we said so. But the presentation invites the reading you object to, and the figure caption now states the tier alongside each result rather than leaving it to the method columns.
On “The badge is about a sample. The listing is about a product.” — Analytics, 13 Jun 2026
I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.
— V. Bhattarai, Kathmandu
That is a better summary of this article’s practical content than our own closing paragraphs. The one thing we would add is that your result is worth publishing wherever you can, because buyer-submitted results are the scarcest and most informative category in the entire corpus.
On “In-use periods, and the ones nobody can give you” — Patient Notes, 13 Jun 2026
Your rotation advice says site does not affect absorption in this class, and then says to rotate anyway. If absorption is unaffected, why bother?
— J. Vasilenko, Chisinau
Because rotation protects tissue rather than controlling absorption. Repeated injection into one small area produces lipohypertrophy, and absorption from lipohypertrophic tissue is blunted and erratic for any injected depot. Rotation prevents the condition that would make site matter. The advice is consistent; we should have made the causal order clearer.
On “In-use periods, and the ones nobody can give you” — Patient Notes, 13 Jun 2026
I have accumulated about eighteen months of used needles in a plastic tub because I did not know where to take them and assumed I would be asked questions. Your paragraph on this is the first time I have seen the situation described rather than lectured about.
— K. Sivertsen, Bergen
Collection services are not interested in what was in the syringe. A pharmacy or local authority sharps point will take a rigid sealed container without inquiry, and the barrier you describe is built entirely of anticipated judgement. We would rather say that plainly than add to the lecturing.
On “In-use periods, and the ones nobody can give you” — Patient Notes, 13 Jun 2026
A quibble on your dead-space figure. You give two to seven microlitres for insulin-type needles, which is right for fixed-needle syringes, but the detachable pen needle plus syringe hub combinations sold in this market are considerably worse and you should say so.
— S. Bergqvist, Malmö
Accepted and amended. The figure we gave applies to integrated fixed-needle insulin syringes; detachable arrangements on a luer fitting can retain an order of magnitude more, which at small injection volumes is a substantial loss. The table now distinguishes them.
On “In-use periods, and the ones nobody can give you” — Patient Notes, 13 Jun 2026
You spend a page on the four-line calculation and then publish a reconstitution table anyway. Are you not providing exactly the pre-computed number you warned against?
— T. Oyelowo, Abeokuta
A fair catch, and the reason the table carries the note it does. It is indexed by both vial mass and diluent volume precisely so that it cannot be read as a single fixed answer, and it is preceded by the derivation. If we thought a reader would take one figure from it and carry that figure across a change of vial, we would remove it.
On “Do you need the top of the ladder?” — Pharmacology, 11 Jun 2026
You keep insisting on peptide content rather than purity when discussing dose certainty. I have looked at a dozen certificates from four different testing services and content is reported on perhaps a third of them. What are readers supposed to do with an absence?
— M. Fitzhenry, Cork
Treat the nominal figure as an upper bound and say so out loud when reasoning about a dose. It is an unsatisfying answer and it is the honest one. We have argued in Analytics that content should be a standard reported field, and we will keep naming the services that report it and those that do not.
On “How far back does this document actually reach?” — The Supply Chain, 11 Jun 2026
The most useful sentence in the piece is the one saying a bad document is not a bad product. I have spent two years on forums watching people conclude the opposite from a missing signature block, and it has made the whole conversation about honesty rather than about paperwork.
— O. Brannigan, Galway
That inversion is the reason we wrote the final section, and we would rather be accused of excessive caution than contribute to it.
On “How far back does this document actually reach?” — The Supply Chain, 11 Jun 2026
I supply research peptides and I want to push back on the specification column point. We sell from a catalogue of six hundred products. Writing a meaningful individual specification for each would take a year of somebody’s time, and a generic one would be exactly the decorative limit your article criticises. What would you actually have us do?
— G. Papadakis, Thessaloniki
A fair challenge. Our answer is that a generic limit stated honestly is better than no limit at all, provided the typical result is also published so a reader can see the margin. What we object to is a decorative limit presented as a control. Publishing your process capability alongside it removes the objection entirely, and costs you a spreadsheet.
On “How far back does this document actually reach?” — The Supply Chain, 11 Jun 2026
Your ten-minute check told me in about ninety seconds that the batch number on my certificate appears nowhere on the vial. I wrote to the supplier and had a straightforward answer within a day: the certificate covers the bulk lot and the vial carries a fill code. I would never have known to ask.
— N. Fairweather, Hamilton
That is exactly the intended use, and the supplier’s answer is the correct one. The remaining question is why the relationship between the two codes is not printed on the document, since it takes a line.
On “How far back does this document actually reach?” — The Supply Chain, 11 Jun 2026
You describe reused chromatogram images as a tell. I work in a contract laboratory and I would note that some data systems export a representative overlay rather than the individual injection, so identical-looking traces can occur legitimately across a batch series. It is still worth asking about; it is not the smoking gun your article implies.
— M. Karlsen, Kristiansand
A useful qualification and the text has been softened. The observation remains worth making; the inference we drew from it was stronger than the practice supports.
On “The instrument was calibrated on Tuesday. Your sample ran on Friday.” — Analytics, 10 Jun 2026
You write that leucine and isoleucine cannot be distinguished by tandem mass spectrometry. That is too absolute. Side-chain fragmentation under high-energy conditions produces diagnostic w and d ions, and the discrimination has been demonstrated repeatedly.
— P. McAlinden, Belfast
Correct, and the text has been amended. The discrimination is achievable under specialised conditions and is not available in any routine service this market uses, which is what we should have written rather than the stronger claim.
On “The instrument was calibrated on Tuesday. Your sample ran on Friday.” — Analytics, 10 Jun 2026
I have spent a week trying to reconcile a certificate’s stated mass of 4113.6 with a figure of 4111.1 I calculated from the sequence, and had convinced myself something was wrong with the vial. It was the isotope convention. Thank you, and also: how is this not stated on every certificate in existence?
— A. Basaraba, Winnipeg, MB
We wish we knew. It is the single most common source of spurious discrepancies reaching this desk, it costs nothing to state, and we have now asked all twenty companies in the dossier programme to add it. Three have.
On “The instrument was calibrated on Tuesday. Your sample ran on Friday.” — Analytics, 10 Jun 2026
Your article says a matching mass does not confirm a sequence, which is correct, and then rather implies that vendors are trading on the ambiguity. I run analytical services and I would put it differently: we report what we measured, in the words our clients ask for. If the Journal wants the word confirmed retired, write to the buyers, not to us.
— M. Sandhu, Amritsar
That is a fair reallocation of the criticism and we accept it. The word is chosen by whoever commissions the report, and laboratories are answering the question they were paid to answer. Our complaint is with the practice, not with the analysts, and the article should have located it more precisely.
On “Why a 0.036-dalton difference is the hardest number in peptide identity” — Explainers, 10 Jun 2026
You write that leucine and isoleucine cannot be distinguished by tandem mass spectrometry. That is too absolute. Side-chain fragmentation under high-energy conditions produces diagnostic w and d ions, and the discrimination has been demonstrated repeatedly.
— E. Marchbank, Perth, WA
Correct, and the text has been amended. The discrimination is achievable under specialised conditions and is not available in any routine service this market uses, which is what we should have written rather than the stronger claim.
On “Why a 0.036-dalton difference is the hardest number in peptide identity” — Explainers, 10 Jun 2026
I have spent a week trying to reconcile a certificate’s stated mass of 4113.6 with a figure of 4111.1 I calculated from the sequence, and had convinced myself something was wrong with the vial. It was the isotope convention. Thank you, and also: how is this not stated on every certificate in existence?
— J. Prendergast, Wollongong, NSW
We wish we knew. It is the single most common source of spurious discrepancies reaching this desk, it costs nothing to state, and we have now asked all twenty companies in the dossier programme to add it. Three have.
On “Why a 0.036-dalton difference is the hardest number in peptide identity” — Explainers, 10 Jun 2026
Your article says a matching mass does not confirm a sequence, which is correct, and then rather implies that vendors are trading on the ambiguity. I run analytical services and I would put it differently: we report what we measured, in the words our clients ask for. If the Journal wants the word confirmed retired, write to the buyers, not to us.
— B. Sundqvist, Turku
That is a fair reallocation of the criticism and we accept it. The word is chosen by whoever commissions the report, and laboratories are answering the question they were paid to answer. Our complaint is with the practice, not with the analysts, and the article should have located it more precisely.
On “Why a 0.036-dalton difference is the hardest number in peptide identity” — Explainers, 10 Jun 2026
I would add one omission to your six lines: the date and nature of the last calibration. A parts-per-million figure from an instrument last calibrated a fortnight ago is a different claim from one calibrated that morning with an internal standard.
— H. Fitzmaurice, Preston
Agreed, and it may be the best suggestion we have received on this subject. It is now a seventh line in the version of the list we send to suppliers, with the note that internal calibration should be stated where it was used.
On “The shortage years, and what they taught about interruption” — The Ledger, 9 Jun 2026
As a prescriber I would push back on your framing of the maintenance gap. We are not practising without evidence; we are practising on pharmacological inference, which is what clinicians do in every field where the trial has not been run. Calling it unevidenced makes reasonable practice sound reckless.
— H. Barreto, Recife
A fair objection and we have adjusted the wording. Our intention was to locate the absence with the people who could have funded the trial rather than with the clinicians managing without it, and on rereading the original paragraph did not achieve that.